chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Paraesthesia, Vertigo
Clinical narrative: Vertigo; Tingling in face, neck and arm; Pain around left ear; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE ;Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 25Mar2021 at 08:30 (at the age of 58-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not take any concomitant medication. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 04:00, the patient experienced vertigo, tingling in face, neck and left arm, and pain around left ear. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events vertigo, tingling in face, neck and left arm, and pain around left ear was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Pyrexia
Clinical narrative: Fatigue (slept 22 out of 24 hr period); Mild temperature (99-101); This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the arm right on 31Mar2021 at 11:15 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, asthma, and allergy to nuts. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN) on unknown date and lisinopril, hydrochlorothiazide (MANUFACTURER UNKNOWN) on unknown date both for unknown indications. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the arm right on 10Mar2021 at 11:15 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 22:45 the patient experienced mild temperature (99-101) and severe fatigue at 23:15 and slept 22 out of 24 hr period. On 31Mar2021, the patient checked the body temperature test and it was 99-101 (units unspecified). The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event mild temperature (99-101) and fatigue (slept 22 out of 24 hr period) was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Significant dirty metal taste that impacted all food consumed; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205), via an unspecified route of administration in the right arm on 23Mar2021 at 13:00 (at the age of 56-years-old), as a single dose for COVID-19 immunisation. Medical history included depression, gout, penicillin allergy and COVID-19. Concomitant medications included escitalopram oxalate (LEXAPRO), allopurinol (MANUFACTURER UNKNOWN) and amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL); all from an unknown date for unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204), via an unspecified route of administration in the left arm on 01Mar2021 (at the age of 56-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 06:00, the patient experienced significant dirty metal taste that impacted all food consumed. It was unknown if therapeutic measures were taken for the reported events. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event significant dirty metal taste that impacted all food consumed was resolving at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Ocular rosacea
Clinical narrative: Rosacea flare up in the left eye; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) in the right arm on 05Mar2021 at 10:30 (at the age of 59-years-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) in the right arm on 26Mar2021 at 10:30 (at the age of 59-years-old) as a single dose for COVID-19 immunisation. Medical history included rosacea and thyroid disorder. The patient previously had taken epinephrine and experienced drug allergy. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), metronidazole cream (MANUFACTURER UNKNOWN) and azelaic acid (AZELEX) all from an unknown date for unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced rosacea flare up in the left eye a couple of days after first vaccine on 08Mar2021. The patient figured it was coincidence.  Second flare up after second vaccine was on the next day. The patient did not receive any treatment for the event. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event rosacea flare up in the left eye was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pharyngeal swelling, Urticaria
Clinical narrative: throat began to swell; hives in several spots; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Mar2021 at 12:00 (at the age of 51-years-old), as a single dose for COVID-19 immunisation. Medical history included known allergy to sulfa. Concomitant medication included venlafaxine hydrochloride (EFFEXOR) for unspecified indication from unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021 at 16:00, approximately 28 hours later, the patient experienced hives in several spots and throat began to swell. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events hives in several spots and throat began to swell and included treatment with 2 benadryl at onset. The clinical outcome of the events hives and throat swelling was recovered on unknown date in 2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Dry throat, Dysphonia, Fatigue
Clinical narrative: Hoarse; Extremely dry throat; Fatigue/tiredness; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8737), via an unspecified route of administration in the left arm on 02Apr2021 at 10:45 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. The patient did not have a history of allergies to food, medications, or other products. Concomitant medications included estradiol (ESTROGEN), naloxone hydrochloride; buprenorphine hydrochloride (SUBOXONE) and venlafaxine hydrochloride (EFFEXOR) all from an unknown date and for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021, the patient experienced hoarse, extremely dry throat, and fatigue /tiredness. The patient did not know if having a hoarse and extremely dry throat was normal. Adverse events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the events hoarse, extremely dry throat, and fatigue /tiredness was not recovered.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Nausea
Clinical narrative: Nausea; Muscle ache; Headache; Tiredness; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER2613) via an unspecified route of administration in the left arm on 02Apr2021 at 10:15 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included autosomal dominant polycystic kidney disease (ADPKD). Concomitant medications included valsartan (MANUFACTURER UNKNOWN), terazosin (MANUFACTURER UNKNOWN), amlodipine (MANUFACTURER UNKNOWN), tolvaptan (MANUFACTURER UNKNOWN) and allopurinol (ALLOPRIM), all from unknown dates and for unknown indications. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 02Apr2021 at 16:00, the patient experienced nausea, muscle ache, headache and tiredness. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event nausea, muscle ache, headache and tiredness was recovered on an unspecified date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Contusion, Headache, Pain in extremity, Renal pain
Clinical narrative: Inability to raise arm without incredible pain; Bruising and swelling from breast to shoulder on right side; Bruising and swelling from breast to shoulder on right side; Kidneys sore; Sick to stomach; Headache; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 01Apr2021 at 16:00 (at the age of 56-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications were not reported. The patient previously took flu shot on an unknown date for immunisation and experienced that her body did not tolerate the flu shot. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 04:00, the patient experienced inability to raise arm without incredible pain, bruising and swelling from breast to shoulder on right side, kidneys were sore, sick to stomach and headaches. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events inability to raise arm without incredible pain, bruising and swelling from breast to shoulder on right side, kidneys were sore, sick to stomach and headaches were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: Inability to raise arm without incredible pain; Bruising and swelling from breast to shoulder on right side; Bruising and swelling from breast to shoulder on right side; Kidneys sore; Sick to stomach; Headache; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the right arm on 01Apr2021 at 16:00 (at the age of 56-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19. Concomitant medications were not reported. The patient previously took flu shot on an unknown date for immunisation and experienced that her body did not tolerate the flu shot. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 04:00, the patient experienced inability to raise arm without incredible pain, bruising and swelling from breast to shoulder on right side, kidneys were sore, sick to stomach and headaches. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the events inability to raise arm without incredible pain, bruising and swelling from breast to shoulder on right side, kidneys were sore, sick to stomach and headaches were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swelling in armpit/lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737), via an unspecified route of administration in the left arm on 01Apr2021 at 09:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. No concomitant medications were reported. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021, since 48 hours after the vaccination, the patient experienced swelling in the armpit/ lymph nodes. The event did not result in a doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the event swelling in the armpit/lymph node. The clinical outcome of the event swelling in the armpit/lymph nodes was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Myalgia
Clinical narrative: Chills; Muscle aches; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the arm right on 01Apr2021 at 14:30 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma which was not ongoing. The patient had cat, dog, dust and outdoor pollen allergies. Concomitant medications included fexofenadine hydrochloride (ALLEGRA) on an unknown date for allergy. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the arm right on 10Mar2021 at 14:30 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 07:00 the patient experienced chills and muscle aches. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events chills and muscle aches were recovered on an unknown date.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Flushing, Pruritus
Clinical narrative: Itching on chin, jawline and cheeks; cheeks would flush with the itching; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EP7534) via an unspecified route of administration in the left arm on 27Mar2021 at 09:15(at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included sulfa allergy(sulfonamide allergy). The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  On 27Mar2021 at 10:00 after 45 min of vaccination, the patient experienced itching on chin and itching continued mostly on chin, jawline and cheeks for 7 days. Occasionally her cheeks would flush with the itching. The adverse events resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment for the reported events which included antihistamines. The clinical outcome of the event itching and flush were  recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Hangover
Clinical narrative: Incredibly soar like a bad hangover; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 04Apr2021 at 10:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. Concomitant medications included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL) and bupropion hydrochloride (WELLBUTRIN). The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6206) via an unspecified route of administration in the right arm on 08Mar2021 at 10:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 00:00, the patient experienced incredibly soar like a bad hangover. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event incredibly soar like a bad hangover was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: Continuous nausea; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 30Mar2021 at 09:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and COVID-19 on unknown date. The patient did not have any allergies to food, medications, or other products. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN, strength 25 mcg) and hydrochlorothiazide (MANUFACTURER UNKNOWN, strength 25 mg) all from an unknown dates taken for unknown indications. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 09Mar2021 at 09:15 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 23:00 the patient experienced continuous nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported adverse event. The clinical outcome of the event continuous nausea was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chills, Pyrexia
Clinical narrative: Chills; Fever; Back pain reporting severe; This is a spontaneous report from a non-contactable consumer. A 51-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the arm left on 01Apr2021 at 10:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. It was unknown whether the patient had any allergies to medications, food, or other products. It was unknown whether the patient had received any concomitant medications. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 the patient experienced chills, fever and back pain (reporting severe). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events chills, fever and back pain (reporting severe) was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Joint stiffness, Malaise, Musculoskeletal stiffness
Clinical narrative: Experienced muscle/joint stiffness for an entire week; Experienced muscle/joint stiffness for an entire week; Extremely fatigued; Felt unwell; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Mar2021 at 10:30 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. Medical history included allergies. Concomitant medications included fish oil (MANUFACTURER UNKNOWN), tocopherol (VIT. E), vitamin d nos (VIT D), glucosamine (MANUFACTURER UNKNOWN) and calcium carbonate (CALCIUM), all from unknown date for an unknown indication. The patient previously took Codeine (MANUFACTURER UNKNOWN) and experienced allergy. The patient previously received first dose of  BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07Mar2021 at 11:45 (at the age of 67-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 28Mar2021 at 11:00, the patient felt unwell, extremely fatigued and experienced muscle/joint stiffness for an entire week. The patient did not receive any treatment for the event. The patient was somewhat better at the time of this report. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events unwell, extremely fatigued and muscle/joint stiffness was resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Acne, Nausea, Pruritus
Clinical narrative: pimples on skin; Itchy skin; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267) via an unspecified route of administration on 14Feb2021 (at the age of 68-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient previously took tetracycline for an unknown indication on an unknown date and experienced drug allergy. The patient previously took nexium for an unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any concomitant medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Feb2021, the patient experienced pimples on skin, itchy skin and nausea. The adverse events did not resulted in doctor or other healthcare professional office/clinic visit/ emergency visit/ department or urgent care.  The patient did not receive any treatment for the reported events. The clinical outcome of the events of pimples, itchy skin and nausea was recovered on an unknown date.  No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, SARS-CoV-2 test
Clinical narrative: loss of taste off and on; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6201) via an unspecified route of administration in the left arm on 25Feb2021 at 11:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included breast cancer on an unknown date in 2014. The patient previously took erythromycin (MANUFACTURER UNKNOWN) on unknown date for unknown indication and experienced drug allergy. Concomitant medications included amitriptyline hydrochloride (ELAVIL) from an unknown date for an unknown indication. The patient also received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 04Mar2021 at 07:00 the patient experienced loss of taste off and on (3 occasions). The adverse event resulted in doctor or other healthcare professional office/clinic visit. The patient underwent SARS-CoV-2 test (Nasal Swab/PCR-polymerase chain reaction) on 05Mar2021and the result was negative. The patient did not receive any treatment for the reported adverse event. The clinical outcome of the event loss of taste off and on was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Chest discomfort, Diarrhoea, Headache, Heart rate
Clinical narrative: Severe diarrhea; headache; resting heartbeat at 95-105 (unspecified units); feeling of weight on chest like they put on for dental X-ray; swollen lymph glands under right arm; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8727) via an unspecified route of administration in the right arm on 25Mar2021 at 18:15 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included shellfish allergy, micro vessel spasms, COVID-19. Concomitant medications included ranolazine (RANEXA) from an unknown date for micro vessel spasms. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 08:00 the patient experienced Severe diarrhea, headache, then 2 days of resting heartbeat at 95-105. Normal resting heartbeat is 72, also had a feeling of weight on chest like they put for dental X-ray. Blood pressure was normal, oxygen rate was 98. Also had swollen lymph glands under right arm. Patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. On an unknown date, the patient measured heartbeat and the result was 95 to 105 (UNSPECIFIED UNIT). On an unknown date, the patient underwent COVID-19 Virus test and the result was Positive. On 27Mar2021, the patient measured blood pressure and the result was normal. On 27Mar2021, the patient measured oxygen rate and the result was 98 (UNSPECIFIED UNITS). The clinical outcome of the events diarrhea, headache, heartbeats increased, chest heaviness, swollen lymph node was recovered on an unspecified date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate increased, Lymphadenopathy, Oxygen saturation, SARS-CoV-2 test
Clinical narrative: Severe diarrhea; headache; resting heartbeat at 95-105 (unspecified units); feeling of weight on chest like they put on for dental X-ray; swollen lymph glands under right arm; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8727) via an unspecified route of administration in the right arm on 25Mar2021 at 18:15 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included shellfish allergy, micro vessel spasms, COVID-19. Concomitant medications included ranolazine (RANEXA) from an unknown date for micro vessel spasms. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 08:00 the patient experienced Severe diarrhea, headache, then 2 days of resting heartbeat at 95-105. Normal resting heartbeat is 72, also had a feeling of weight on chest like they put for dental X-ray. Blood pressure was normal, oxygen rate was 98. Also had swollen lymph glands under right arm. Patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. On an unknown date, the patient measured heartbeat and the result was 95 to 105 (UNSPECIFIED UNIT). On an unknown date, the patient underwent COVID-19 Virus test and the result was Positive. On 27Mar2021, the patient measured blood pressure and the result was normal. On 27Mar2021, the patient measured oxygen rate and the result was 98 (UNSPECIFIED UNITS). The clinical outcome of the events diarrhea, headache, heartbeats increased, chest heaviness, swollen lymph node was recovered on an unspecified date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Arm soreness at the site of the reaction that peaked approximately 12 hours after injection; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EP 6955) via an unspecified route of administration in the right arm on 01Apr2021 at 09:15 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure high and sulfonamides allergy. Concomitant medications included amlodipine (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA), mineral nos, vitamin nos (CENTRUM ADULT) and lactobacillus nos (CULTURELLE), all from unknown dates and for unknown indications. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL 3247) via an unspecified route of administration in the left arm on 11Mar2021 at 09:45 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 01Apr2021, the patient experienced arm soreness at the site of the reaction that peaked approximately 12 hours after injection. The patient did not receive any treatment for the reported event. The adverse event did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event arm soreness at the site of the reaction was recovered on an unknown date in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache
Clinical narrative: Fatigue; Slight headache; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150), via an unspecified route of administration in the arm left on 31Mar2021 at 11:30 hours (at the age of 37-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient had no known allergies to medications, food, or other products. Concomitant medications included LARISSA, ADVIL, magnesium (MANUFACTURER UNKNOWN). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. It was reported that the patient did not received any other vaccines within 4 weeks prior to the COVID vaccine. On 31Mar2021 at 14:00 hours, the patient experienced fatigue and slight headache. The adverse events did not result in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcomes of the events fatigue and slight headache were recovered on an unspecified date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site pruritus
Clinical narrative: Large bumps around injection site; Large bumps around injection site with itching; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 05Apr2021 at 09:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any medication within two weeks of vaccination. The patient previously received morphine (MANUFACTURER UNKNOWN) and pethidine (DEMEROL) on an unknown date for unknown indication and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 11:15, the patient experienced large bumps around the injection site and itching. The patient did not receive any treatment for the events large bumps around the injection site and itching. The events did not result in doctor or other healthcare professional office/clinic visits, and the emergency room/department or urgent care. The clinical outcome of the events large bumps around the injection site and itching was not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Hyperhidrosis, Nausea, Vision blurred
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 31Mar2021 at 08:00 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included pollen allergy on an unknown date. Concomitant medications and past drug were not reported. Prior to the vaccination, it was unknown if the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination and any other medications within 2 weeks of vaccination. On 31Mar2021 at 08:15 the patient experienced blurry vision, extreme dizziness, vomiting urge (nausea) and profusely sweating (sweat dripping of the face). The patient reported that the events lasted for about 3 minutes and nothing after that. The patient was concerned and worried to take the second shot on Apr2021. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the events. The clinical outcome of the events blurry vision, extreme dizziness, vomiting urge (nausea) and profusely sweating (sweat dripping of the face) was resolved on 31Mar2021 at 08:18. No follow-up attempts are needed ; information about lot/batch number cannot be obtained.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Rash macular
Clinical narrative: A quarter-size red spot under the right armpit with a rash spreading out from it; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208), via an unspecified route of administration in the arm left on 21Mar2021 at 16:15 (at the age of 74-year-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient was allergic to penicillin. Concomitant medications included aspirin (MANUFACTURER UNKNOWN) at a dose of 81 mg started on an unspecified date for an unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021, the patient developed a quarter-size red spot under the right armpit with a rash spreading out from it. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event a quarter-size red spot under the right armpit with a rash spreading out from it was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Parosmia
Clinical narrative: Phantosmia - cigarette smoke; This is a spontaneous report from a contactable consumer, the patient. A 52-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 31Mar2021 at, 17:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism, GERD (Gastroesophageal reflux disease), depression and anxiety. The patient had known allergies to sulfa drugs. Concomitant medications included bupropion hydrochloride (WELLBUTRIN), fluoxetine hydrochloride (PROZAC), pantoprazole sodium sesquihydrate (PROTONIX), levothyroxine sodium (SYNTHROID) and fish oil (MANUFACTURER UNKNOWN) all the drugs started on an unknown date, for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 the patient experienced phantosmia - cigarette smoke. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of reported event. The clinical outcome of the event phantosmia - cigarette smoke was not resolved.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal pain upper, Musculoskeletal chest pain
Clinical narrative: woke up from sleep with stomachache, which spread and stayed inribs, both sides, front, in the middle ofthe rib cage.; woke up from sleep with stomachache, which spread and stayed in ribs, both sides, front, in the middle ofthe rib cage.; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 02Apr2021 at 11:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have a history of allergies to medications, food, or other products. Concomitant medications included doxycycline (MANUFACTURER UNKNOWN), atorvastatin (LIPITOR), acyclovir (MANUFACTURER UNKNOWN), probiotic (MANUFACTURER UNKNOWN) and aspirin (MANUFACTURER UNKNOWN). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 04:00, the following night (36 hours post shot), the patient woke up from sleep with stomach ache, which spread and stayed in ribs. Ache in both sides, front, in the middle of the rib cage. It got better in the morning and started up in the next night, but less severe. The pain was diffuse and strong. Adverse events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported events. The clinical outcome of the events woke up from sleep with stomach ache, which spread and stayed in ribs, both sides, front, in the middle of the rib cage was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Feeling abnormal, Hypoaesthesia oral
Clinical narrative: Numbness in tongue; Numbness in lips; Dizziness; Brain fog; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 30Mar2021 at 16:30(at the age of 43-year-old) as a single dose for COVID-19 immunisation. The medical history was reported as no. Concomitant medications were not reported. The patient had no known allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EL9269) via an unspecified route of administration in the left arm on 09Mar2021 at 16:45(at the age of 43-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 16:45, few days after second dose, the patient experienced numbness in tongue and lips, dizziness and brain fog(fuzzy head). The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.  The clinical outcome of events numbness in tongue, numbness in lips, dizziness and brain fog were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.